Local News

• Dick Bond leaving Tyson Foods  Dick Bond, president and chief executive officer of Tyson Foods, announced he is leaving the company, effective immediately. Leland Tollett, former chairman and CEO of the company, has agreed to return to the company as President and CEO on an interim basis.
  Tyson Foods, Inc. January 05, 2009  
• PPD enters into strategic collaboration with Merck  PPD announced it has entered into a strategic collaboration with Merck & Co. involving vaccine testing and assay development. Under the agreements, PPD purchased Merck's 130,000 square-foot vaccine testing laboratory and related equipment in Wayne, Penn.
  PPD, Inc. January 05, 2009  
• Albemarle completes the sale of its Port de Bouc, France facility to ICIG  Albemarle and International Chemical Investors Group (ICIG) announced today that Albemarle Chemicals SAS, a wholly owned affiliate of Albemarle Corporation, has completed the sale of its facility in Port de Bouc, France to Azur Chimie SAS, a wholly owned affiliate of ICIG.
  Albemarle Corporation January 02, 2009  
• FDA Cardio Renal Advisory Committee to review Daiichi Sankyo, Lilly drug prasugrel  Daiichi Sankyo Company and Eli Lilly and Company confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009.
  Eli Lilly and Company December 31, 2008  
• Johnson & Johnson completes acquisition of Omrix Biopharmaceuticals  Johnson & Johnson announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.
  Johnson & Johnson December 30, 2008  
• Celera and Abbott revise strategic alliance  Celera and Abbott announced a revision of the strategic alliance agreement between the two companies. Under a new distribution agreement, Abbott will exclusively distribute certain molecular diagnostic products manufactured by Celera.
  Celera Corporation December 29, 2008  
• Johnson & Johnson completes tender offer for Omrix Biopharmaceuticals  Johnson & Johnson announced that stockholders of Omrix Biopharmaceuticals tendered approximately 16,749,152 shares of Omrix common stock, including approximately 1,293,924 shares subject to guaranteed delivery procedures, representing approximately 97.8% of Omrix's outstanding common stock.
  Johnson & Johnson December 27, 2008  
• AstraZeneca receives FDA Complete Response Letter on Seroquel XR  AstraZeneca announced the company has received a Complete Response Letter (CRL) from the FDA asking for additional information for the supplemental New Drug Application for SEROQUEL XR Extended Release Tablets for the treatment of Major Depressive Disorder (MDD) in adult patients.
  AstraZeneca December 24, 2008  
• Abbott and Isis announce Hart-Scott-Rodino clearance of Abbott's acquisition  Isis Pharmaceuticals and Abbott announced that they have received clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for Abbott's purchase of the remaining equity ownership in Ibis Biosciences, an Isis subsidiary.
  Isis Pharmaceuticals, Inc. December 23, 2008  
• Johnson & Johnson extends tender offer for Omrix Biopharmaceuticals  Johnson & Johnson announced it has extended its previously announced cash tender offer, through its wholly-owned subsidiary, Binder Merger Sub, for all outstanding shares of common stock of Omrix Biopharmaceuticals until 12:00 midnight (EST), on Dec. 26, 2008, unless further extended.
  Johnson & Johnson December 22, 2008  

   (next 10 articles)